Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy in South Korea and Taiwan
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Sanofi
- 18 May 2016 Status changed from active, no longer recruiting to completed.
- 23 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 02 Oct 2015 Planned End Date changed from 1 May 2016 to 1 Apr 2016 as per ClinicalTrials.gov record.